Related Experiment Videos
Challenges in bringing the bench to bedside in drug development for SLE
Joan T Merrill1, Doruk Erkan, Jill P Buyon
1Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, 825 Northeast 13th Street Oklahoma City, Oklahoma 73104, USA.
Nature Reviews. Drug Discovery
|December 2, 2004
Summary
Systemic lupus erythematosus (SLE) treatments are inadequate, with no new drugs approved in 30 years. Advances in understanding lupus pathogenesis offer new hope for developing effective therapies for this autoimmune disease.
Area of Science:
- Immunology
- Rheumatology
- Genetics
Background:
- Current treatments for systemic lupus erythematosus (SLE) are insufficient for many patients.
- No new medications for SLE have been approved in the last three decades.
- Drug development for SLE has faced significant challenges since the mid-1990s.
Purpose of the Study:
- To highlight the inadequacy of current SLE standard of care.
- To discuss the obstacles in developing new SLE medications.
- To explore the implications of updated lupus pathogenesis models for future drug discovery.
Main Methods:
- Review of existing literature on SLE treatment and drug development.
- Analysis of current models of lupus pathogenesis.
- Discussion of genetic factors contributing to SLE susceptibility.
Main Results:
- Established models of lupus pathogenesis provide a framework for understanding individual susceptibility.
- Heterogeneous genetic defects play a role in SLE development.
- These insights could guide the development of targeted therapies.
Conclusions:
- There is a critical unmet need for novel SLE therapies.
- Understanding the genetic basis of SLE is crucial for advancing drug development.
- Increased public awareness and research momentum are driving efforts to overcome development hurdles.